Award of Shares under SIP and Director Dealings

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020, which is available to all of the Company's UK based employees, including Directors.

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 228,940 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.14 per Ordinary Share on 22 July 2025 to meet its obligations under the SIP (the "Partnership Shares"). Under the terms of the SIP, the Company is required to issue or make available to the SIP two Ordinary Shares in the Company for each Partnership Share purchased (being 457,880 Ordinary Shares in total for the six-month period to end of June 2025, the "Matching Shares"). Fiduchi currently holds 2,664,126 unallocated Ordinary Shares within the SIP which can be utilised to satisfy the Company's obligation to issue or make available Matching Shares. Accordingly, 457,880 Ordinary Shares will be utilised by Fiduchi as trustee of the SIP to meet this matching obligation, and no new Ordinary Shares are required to be issued to satisfy the Company's obligations under the SIP.

Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors"), have acquired Partnership Shares at a price of £0.14 per share and received Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following the Transaction, the Participating Directors' shareholdings in the Company are as set out in the table below:

Notes:

1 Includes shares held by Mr Gulliford's wife.

2 Includes shares held by Mr Rees's wife and PCAs.

• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.14 6,429
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-07-22 BST
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Craig Gulliford
• Position / status CEO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 12,858
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-07-22 BST
• Place of the transaction Off-market

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.14 6,429
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-07-22 BST
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 12,858
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-07-22 BST
• Place of the transaction Off-market